Estrogens esterified
Amnestrogen, Duavee, Estratab, Evex, Femogen, Menest, Menrium, Milprem, Pmb, Premarin, Premphase, Prempro (estrogens, esterified) is an unknown pharmaceutical. Estrogens, esterified was first approved as Amnestrogen on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| covaryx | unapproved drug other | 2020-01-25 |
| covaryx covaryx | unapproved drug other | 2013-02-26 |
| eemt | unapproved drug other | 2020-01-22 |
| eemt eemt | unapproved drug other | 2013-03-01 |
| esterified estrogens and methyltestosterone | unapproved drug other | 2025-02-10 |
| esterified estrogens and methyltestosterone full strength esterified estrogens and methyltestosterone half strength | unapproved drug other | 2025-03-10 |
| esterified estrogens and methytestesterone | unapproved drug other | 2022-11-25 |
| estratest f.s. | unapproved drug other | 2024-09-06 |
| estratest f.s. estratest h.s. | unapproved drug other | 2024-06-15 |
| estratest fs estratest hs | unapproved drug other | 2025-03-10 |
Show 1 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alcohol withdrawal delirium | EFO_1000800 | D000430 | — |
| anxiety disorders | EFO_0006788 | D001008 | F41.1 |
Agency Specific
FDA
EMA
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03A: Hormonal contraceptives for systemic use
— G03AA: Progestogens and estrogen systemic contraceptives, fixed combinations
— G03AA14: Nomegestrol and estradiol
— G03AA17: Medroxyprogesterone and estradiol
— G03AB: Progestogens and estrogens systemic contraceptives, sequential preparations
— G03AB08: Dienogest and estradiol
— G03C: Estrogens, sex hormones and modulators of the genital system
— G03CA: Natural and semisynthetic estrogens, plain
— G03CA03: Estradiol
— G03CA53: Estradiol, combinations
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01C: Hypothalamic hormones
— H01CC: Anti-gonadotropin-releasing hormones
— H01CC53: Elagolix, estradiol and norethisterone
— H01CC54: Relugolix, estradiol and norethisterone
HCPCS
No data
Clinical
Clinical Trials
158 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menopause | D008593 | EFO_0003922 | N95 | 6 | 8 | 4 | 7 | 2 | 27 |
| Postmenopause | D017698 | — | — | 8 | 5 | 3 | 2 | 3 | 21 |
| Atrophy | D001284 | — | — | 2 | — | 5 | 1 | 2 | 10 |
| Atrophic vaginitis | D059268 | EFO_1001271 | — | 2 | — | 3 | 3 | 1 | 9 |
| Hot flashes | D019584 | — | — | — | 1 | 4 | 2 | 2 | 9 |
| Vaginitis | D014627 | EFO_0005757 | N76 | 3 | — | 1 | 3 | 2 | 9 |
| Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | — | 1 | 4 | 2 | 7 |
| Prolapse | D011391 | — | — | — | — | 1 | 4 | 2 | 7 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | 4 | 2 | 6 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | 2 | 2 | 1 | — | 5 |
Show 27 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 2 | 18 | 13 | — | 3 | 32 |
| Adenocarcinoma | D000230 | — | — | 1 | 8 | 2 | — | — | 11 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 4 | 2 | — | 3 | 11 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | 6 | — | 2 | 9 |
| Carcinoma | D002277 | — | C80.0 | — | 5 | 1 | — | — | 6 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 2 | 5 | — | — | 6 |
| Neoplasms | D009369 | — | C80 | — | 3 | 1 | — | — | 4 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | 3 | — | — | 4 |
| Coronary disease | D003327 | — | — | — | 1 | 4 | — | — | 4 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 4 | — | — | 4 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 2 | — | — | — | 2 |
| Lymphatic metastasis | D008207 | EFO_1001364 | — | — | 1 | — | — | — | 1 |
| Risk reduction behavior | D040242 | — | — | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
| Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
| Carcinoma in situ | D002278 | — | D09.9 | — | 1 | — | — | — | 1 |
| Breast carcinoma in situ | D000071960 | — | D05 | — | 1 | — | — | — | 1 |
| Ductal carcinoma breast | D018270 | — | — | — | 1 | — | — | — | 1 |
| Intraductal carcinoma noninfiltrating | D002285 | — | D05.1 | — | 1 | — | — | — | 1 |
Show 20 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 2 | — | — | — | 1 | 3 |
| Estrogen replacement therapy | D015914 | — | — | 2 | — | — | — | — | 2 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | 1 | — | — | — | 1 | 2 |
| Premature menopause | D008594 | — | E28.31 | 2 | — | — | — | — | 2 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | — | — | 1 |
| Sleep | D012890 | GO_0030431 | — | 1 | — | — | — | — | 1 |
| Metrorrhagia | D008796 | — | N92.1 | 1 | — | — | — | — | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 1 | 1 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | — | 1 | 1 |
| Gender dysphoria | D000068116 | — | F64 | — | — | — | — | 1 | 1 |
| Breast density | D000071060 | — | — | — | — | — | — | 1 | 1 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | — | — | 1 | 1 |
| Male breast neoplasms | D018567 | — | — | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Estrogens esterified |
| INN | _ |
| Description | 17beta-estradiol is the 17beta-isomer of estradiol. It has a role as an estrogen, a human metabolite, an EC 1.2.3.1 (aldehyde oxidase) inhibitor, a Daphnia magna metabolite, a mouse metabolite and a geroprotector. It is a 17beta-hydroxy steroid and an estradiol. |
| Classification | Unknown |
| Drug class | estrogens; steroids (androgens, anabolics) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 141290-02-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201468 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09381 |
| UNII ID | 3ASP8Q3768 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Premarin – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,034 documents
View more details
Safety
Black-box Warning
Black-box warning for: Covaryx, Covaryx covaryx, Eemt, Eemt eemt, Esterified estrogens and methyltestosterone, Esterified estrogens and methyltestosterone full strength esterified estrogens and methyltestosterone half strength, Esterified estrogens and methytestesterone, Estratest f.s., Estratest f.s. estratest h.s., Estratest fs estratest hs, Menest
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
61,069 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use